A prospective, open-label study was conducted to assess the response to indinavir, efavirenz, and adefovir in human immunodeficiency virus (HIV)-infected patients experiencing viral rebound while receiving therapy with nelfinavir-containing regimens, to determine whether the protease genotype influenced the outcome of the salvage regimen. Genotyping from 29 nelfinavir failures revealed D30N in 17 (59%) and L90M in 11 (38%) cases. Suppression to <400 viral RNA copies/mL was achieved at week 48 in 56% of patients with the D30N virus versus 18% of patients with the L90M virus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1086/368287 | DOI Listing |
Publication Analysis
Top Keywords
indinavir efavirenz
8
efavirenz adefovir
8
treatment indinavir
4
adefovir failure
4
failure nelfinavir
4
nelfinavir therapy
4
therapy prospective
4
prospective open-label
4
open-label study
4
study conducted
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!